Share on LinkedInShare on LinkedIn

ARTICLE · 18 NOVEMBER 2024

Amgen Launches Pavblu™ As The First EYLEA® Biosimilar In The U.S.

Amgen announced during its Q3 2024 Earnings Call that it had launched Pavblu™ (aflibercept-ayyh) as the first biosimilar of Regeneron's EYLEA® (aflibercept) to be marketed in the U.S.

United StatesIntellectual Property

Amgen announced during its Q3 2024 Earnings Call that it had launched Pavblu" (aflibercept-ayyh) as the first biosimilar of Regeneron's EYLEA® (aflibercept) to be marketed in the U.S. The launch follows the Federal Circuit's decision on October 22, 2024 (CAFC Appeal No. 24-2351) to deny a temporary injunction that would prevent Pavblu" from launching at-risk while Regeneron appeals an earlier District Court (Case No. 1:24-cv-00039 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)) denial of a preliminary injunction against Pavblu" (previously reported Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu" After Federal Circuit Lifts Temporary Injunction). The litigation and appeal remain ongoing.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from